Personalized medicine

Resolve Biosciences Sets New Standard for Single-Cell Spatial Analysis with Launch of Fully Automated Molecular Cartography™ Workflow

Retrieved on: 
Tuesday, June 7, 2022
Research, Infectious Diseases, Genetics, Biotechnology, Health, Agriculture, Natural Resources, Science, Oncology, Other Science, Inflammation Research, Â, Biomarker, Macrophage, Infection, German Resource Center for Genome Research, Doctor of Philosophy, Stanford University School of Medicine, Inflammation, Multimedia, Neurology, Technology, German Cancer Research Center, Research, Vlaams Instituut voor Biotechnologie, Gold, Tissue, View, Novo Nordisk Foundation Center for Protein Research, Observation, Agriculture, Lunch, Personalized medicine, CEO, List of life sciences, Center, Monheim am Rhein, B cell, Laboratory, Mouse, Molecular medicine, University of Copenhagen Nano-Science Center, Neuroscience, Cell, Liver, University, Patient, DNA, Steatosis, Science, Cartography, Disease, Fatty liver disease, VIB, Developmental biology, Pleasure, Systems biology, DKFZ, Medical imaging, Pharmaceutical industry, Microscope, Genetics, Genomics

Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced the launch of its commercial Molecular Cartography workflow and the installation of the first systems at leading research institutions around the world.

Key Points: 
  • Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced the launch of its commercial Molecular Cartography workflow and the installation of the first systems at leading research institutions around the world.
  • Previously, these customers accessed the power of the system through the companys commercial Molecular Cartography service offering and early access program.
  • Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of spatial biology.
  • Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences.

Cellworks Singula™ TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies

Retrieved on: 
Monday, June 6, 2022
Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Oncology, NGS, Cell, Research, Nominal interest rate, Progression-free survival, Personalized medicine, Survival, Harvard Medical School, Neuro, Artificial intelligence, Abstract, Baptist Health South Florida, The Cancer Genome Atlas, Baptist Health, Software, Brain, Group, IDH, Guideline, Disease, GBM, Glioblastoma, Center, GEA, Agilent Technologies, Immunology, Patient, Drug combination, Trial of the century, TRI, CBM, Dana–Farber Cancer Institute, MD, NCCN, Radiation, Sequoia Capital, PFS, MGMT, Neurology, OS, TCGA, LR, UnitedHealth Group, Pharmaceutical industry, Medical device, Medical imaging

In this study, Singula TRI provided patient-specific estimates of OS and PFS for 18 NCCN guideline GBM therapies and provided predictive value beyond physician-prescribed therapy, patient age, patient sex, and MGMT methylation status.

Key Points: 
  • In this study, Singula TRI provided patient-specific estimates of OS and PFS for 18 NCCN guideline GBM therapies and provided predictive value beyond physician-prescribed therapy, patient age, patient sex, and MGMT methylation status.
  • The findings from using this approach in the myCare-024-04 study suggest that biosimulating guideline GBM therapies for newly diagnosed GBM patients can positively effect clinical outcomes.
  • Cellworks Singula TRI facilitates selection of optimal personalized therapies by providing patient-specific estimates of OS and PFS for 18 NCCN guideline GBM therapies.
  • This information may be used to estimate increases in OS and PFS when comparing Singula TRI recommended therapies verses standard care.

Cellworks Singula™ TRI Predicts Personalized Treatment Outcomes for Esophageal Adenocarcinoma Patients Beyond Standard Clinical Factors

Retrieved on: 
Monday, June 6, 2022
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, DFS, Cambridge University Hospitals NHS Foundation Trust, NGS, University, Research, Nominal interest rate, Personalized medicine, Survival, SC, Artificial intelligence, Software, Group, Female, GEA, CRUK, TP53, Agilent Technologies, Male, Immunology, Patient, Drug combination, DNA, Trial of the century, TRI, CBM, MD, Sequoia Capital, OS, N2, Cancer, UnitedHealth Group, Pharmaceutical industry, TRG

The next step is to evaluate whether biosimulation-informed therapy selection can be used prospectively to improve the survival of GEA patients.

Key Points: 
  • The next step is to evaluate whether biosimulation-informed therapy selection can be used prospectively to improve the survival of GEA patients.
  • There are limited treatment options for this cancer type and we look forward to testing the Cellworks personalized therapy predictions in a prospective trial.
  • The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients.
  • Cellworks SingulaTherapy Response Index (TRI) provided additional predictive information for OS and DFS beyond physician prescribed treatment and standard clinical factors.

Global Biomarkers Market Outlook & Forecast 2022-2027: Increase In Number of Pipeline Biomarkers & Rising Adoption of Biomarkers In Disease Diagnostics - ResearchAndMarkets.com

Retrieved on: 
Friday, June 3, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Biomarker discovery, Biomarker, APAC, Prognosis, Precision medicine, Research, Parkinson's disease, D, Cancer, Diagnosis, Patient, Adoption, Geography, Prevalence, Institute of Information Technology Advancement, Industry, Competitive analysis, Drug discovery, Alzheimer's disease, Drug development, CAGR, Medical imaging, Personalized medicine

The "Biomarkers Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biomarkers Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • In-depth Analysis and Data-driven Insights on the Vendor Landscape, Competitive Analysis, and Critical Market Strategies are Included in this Global Biomarkers Market Report.
  • Oncology dominated the indication segment because biomarkers are being largely used for cancer research and diagnostics due to its high prevalence worldwide.
  • Increased Adoption of Biomarkers in Personalized Medicine is driving the global biomarkers market growth.

Sarah Cannon to Present Latest Oncology Research Insights at 2022 ASCO® Annual Meeting

Retrieved on: 
Thursday, June 2, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, NUALS Arts and Literary Annual Meet, MBC, Doctor of Philosophy, Business, Sarah Cannon Research Institute, RCC, Metastatic breast cancer, Annual, Nivolumab, Research, Abstract (summary), FACP, Drug development, Melanoma, Cancer, Breast cancer, Personalized medicine, Skin cancer, HCA, Randomness, Development, GTPase, Program, Clinical, MPH, FIH, CRO, University, CDT, OVC, Jefferson Health, Society, Lung cancer, Annual general meeting, Wilms' tumor, American Society of Clinical Oncology, 2021 Essex County Council election, MS, Workforce, Safety, Clinical trial, Pharmaceutical industry, HealthONE, MD, Patient, Telehealth, Immunotherapy

Today, Sarah Cannon Research Institute announced that it will highlight its latest cancer research insights through more than 140 abstracts and presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago and online from June 3-7, 2022.

Key Points: 
  • Today, Sarah Cannon Research Institute announced that it will highlight its latest cancer research insights through more than 140 abstracts and presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago and online from June 3-7, 2022.
  • Experts from across Sarah Cannon Research Institutes network will join oncology leaders from around the globe to discuss the latest research findings that are accelerating progress in the fight against cancer.
  • Abstracts and presentations with Sarah Cannon experts as first authors will be presented by:
    Meredith McKean, MD, MPH, Director, Melanoma & Skin Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology
    Sarah Cannon Research Institute is the research arm of HCA Healthcares Cancer Institute, Sarah Cannon.
  • Sarah Cannons strategic site network includes: Hematology/Oncology Clinic, Messino Cancer Centers, Sarah Cannon Research Institute at Florida Cancer Specialists, Sarah Cannon Research Institute at HCA Midwest Health, Sarah Cannon Research Institute at HealthONE, Sarah Cannon Research Institute at Tennessee Oncology, Sarah Cannon Research Institute - United Kingdom, Sidney Kimmel Cancer Center at Jefferson Health, The Stephenson Cancer Center at the University of Oklahoma, and Zangmeister Cancer Center.

Ultima Genomics Delivers the $100 Genome

Retrieved on: 
Tuesday, May 31, 2022
Cancer Research UK, Whitehead Institute, Health, Software, D1 Capital Partners, Genome, Company, General Atlantic, DNA, Stanford University, Harvard University, Multimedia, Biology, Baylor University, MIT, Biomedical Research, Architecture, Research, RNA-Seq, Personalized medicine, Center, Broad, Genomics, Methylation, Neoplasm, Founders Fund, Broad Institute, Machine learning, Adoption, Ultima, Khosla Ventures, Baylor College of Medicine, BioRxiv, Diagnosis, German Resource Center for Genome Research, Antibiotics, Vaccine, Speed of light

NEWARK, Calif., May 31, 2022 /PRNewswire/ -- Today Ultima Genomics emerged from stealth mode with a new high-throughput, low-cost sequencing platform that delivers the $100 genome.  Ultima's goal is to unleash a new era in genomics-driven research and healthcare, and it has secured approximately $600 million in backing from leading investors who share this vision.

Key Points: 
  • NEWARK, Calif., May 31, 2022 /PRNewswire/ -- Today Ultima Genomics emerged from stealth mode with a new high-throughput, low-cost sequencing platform that delivers the $100 genome.
  • "Ultima Genomics' architecture will revolutionize sequencing and take what we can do to a whole new level," said Michael Snyder, Director of the Center for Genomics and Personalized Medicine at Stanford University.
  • "We have seen the quality of Ultima Genomics sequencing in millions of single cells, and now are initiating even larger experiments that weren't previously feasible."
  • Ultima Genomics is unleashing the power of genomics at scale.

Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference

Retrieved on: 
Friday, May 27, 2022
Knowledge, U.S. Securities and Exchange Commission, Mortality, Legislation, Plasma, Conference, Data, Monocyte, Immune system, OTCQB, National Early Music Association, Clinical trial, COVID-19, Method, Research, Brain, Alzheimer's disease, Pressure, Cell cycle, GLOBE, Company, IC50, Solution, Coronavirus, Neurodegeneration, Pharma, Biotechnology, Synthase, PCR, Apoptosis, COVID, Cancer, Severe acute respiratory syndrome coronavirus 2, Pacific Time Zone, Cancer immunotherapy, TMB-2, Patient, Ivermectin, Lymphocyte, Neuron, Personalized medicine, Technology, MERS, TBIA, CEO, Pharmaceutical industry, Medical imaging

Tollovid's 3CL protease IC50 binding affinity is at least ten times (10x) as strong as Ivermectins published 3CL protease IC50 binding affinity.

Key Points: 
  • Tollovid's 3CL protease IC50 binding affinity is at least ten times (10x) as strong as Ivermectins published 3CL protease IC50 binding affinity.
  • Tollovid Dailys 3CL protease IC50 binding affinity is at least two and a half times (2.5x) as Ivermectin.
  • Tollovir has successfully completed a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19.
  • Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19.

Neuvivo Announces Addition of Michael Snyder, PhD - Chair of the Department of Genetics at the Stanford School of Medicine - to Scientific Advisory Board

Retrieved on: 
Thursday, April 14, 2022
ALS, CEO, Biology, German Resource Center for Genome Research, Macrophage, Biotechnology, California Institute for Quantitative Biosciences, Prognosis, Postdoctoral researcher, Stanford University, Developmental Biology (journal), Hisba, Coronavirus Scientific Advisory Board (Turkey), Chemistry, Center, Yale University, Snyder, Central nervous system, Doctor of Philosophy, Patient, Stanford University School of Medicine, CSO, Genome, Health, Immune system, University of Rochester, CT, Secondary research, Method, Neurodegeneration, Personalized medicine, Gene, PALO, De novo, RNA-Seq, Life Technologies, University, IPOP, Proteomics, Medical device, Technology, Illumina, Genomics, Genetics, Philip H. Mirvis

PALO ALTO, Calif., April 14, 2022 /PRNewswire/ -- Neuvivo today announced that Michael Snyder, PhD, will join the company's Scientific Advisory Board. Dr. Snyder is one of the world's leading experts in genetics and is credited with advancing the fields of functional genomics, personalized medicine and proteomics. Since 2009 Dr. Snyder has been the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine, Stanford University School of Medicine. His lab is recognized as the first to perform a large-scale functional genomics project in any organism and he is recognized for combining novel "omics" technologies to perform the first-ever longitudinal integrative personal omics profile (iPOP) of people to assess disease risk and monitor disease states for personalized medicine.

Key Points: 
  • PALO ALTO, Calif., April 14, 2022 /PRNewswire/ -- Neuvivo today announced that Michael Snyder, PhD, will join the company's Scientific Advisory Board.
  • Dr. Snyder is one of the world's leading experts in genetics and is credited with advancing the fields of functional genomics, personalized medicine and proteomics.
  • Since 2009 Dr. Snyder has been the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine, Stanford University School of Medicine.
  • He did Postdoctoral Research at the Stanford University School of Medicine under Dr. Ronald Davis.

Cellworks Personalized Therapy Biosimulation Study Identifies Novel Biomarkers Predictive of Response in AML Patients

Retrieved on: 
Tuesday, December 14, 2021
Data Management, Biotechnology, Technology, Health, Oncology, Other Science, Research, Software, Genetics, Science, Clinical Trials, Daunorubicin, Personalized medicine, FDA, AML, Immunology, Etoposide, Idarubicin, Toxicity, Abstract, VP16, Biomarker, Group, Artificial intelligence, PubMed, UnitedHealth Group, Research, Patient, TCGA, Agilent Technologies, Exposition, Software, CBM, MD, Drug combination, Sequoia Capital, ASH, Trial of the century, Biosimulation, Precision medicine, Cytarabine, Society, Pharmaceutical industry, Medical imaging

In the study, the Cellworks Biosimulation Platform and CBM was used to assess cytarabine (ARA-C) and anthracycline response and novel biomarker response criteria for the addition of etoposide (VP16) in AML.

Key Points: 
  • In the study, the Cellworks Biosimulation Platform and CBM was used to assess cytarabine (ARA-C) and anthracycline response and novel biomarker response criteria for the addition of etoposide (VP16) in AML.
  • The study found that Cellworks biosimulation identifies novel biomarkers that predict therapy response in AML patients, which offers the opportunity to tailor FDA-approved chemotherapy regimens to each patient to improve disease control and minimize toxicity.
  • From comprehensive genomic inputs, the Cellworks Biosimulation Platform identifies pathway based polygenic biomarkers that predict the efficacy of novel drug combinations and new drugs for AML patients, said Dr. Michael Castro, MD, Chief Medical Officer at Cellworks.
  • The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients.

Cellworks Personalized Biosimulation Study Identifies Novel MDS Biomarkers and Immune Modulation Predictive of Therapy Response

Retrieved on: 
Tuesday, December 14, 2021
Data Management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Research, Software, Science, Clinical Trials, TRRAP, Personalized medicine, Clinical trial, MDS, Abstract, AZA, Disease, CBM, Drug resistance, Antigen, Biosimulation, HMA, Biomarker, Artificial intelligence, Myelodysplastic syndrome, CAV1, DAC, KDM4C, IFNA1, JAK2, MD, ASH, Society, Monosomy, Group, HIPK2, Research, Exposition, Agilent Technologies, DNA, VPA, HDAC, Software, Drug combination, Sequoia Capital, GSK3B, CD8, CTNNB1, Immunology, Azacitidine, UnitedHealth Group, Escape Room, Neoplasm, Patient, CD274, Medical device, Vaccine, Pharmaceutical industry, Decitabine

In the ASH Abstract 3690 study, the Cellworks Biosimulation Platform and CBM identified immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.

Key Points: 
  • In the ASH Abstract 3690 study, the Cellworks Biosimulation Platform and CBM identified immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.
  • The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients.
  • Cellworks Biosimulation Platform found that signaling pathway consequences related to CTNNB1 and c-MYC modulation predict response to DAC + VPA.
  • Biosimulation using the Cellworks Computational Omics Biology Model (CBM) identifies immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.